Dianthus price target raised to $130 from $100 at Clear Street

Clear Street analyst Bill Maughan raised the firm’s price target on Dianthus (DNTH) to $130 from $100 and keeps a Buy rating on the shares. The firm is citing the company’s interim update from the ongoing Phase 3 CAPTIVATE trial for claseprubart in chronic inflammatory demyelinating polyneuropathy, the analyst tells investors in a research note.